This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Profound Medical CAPTAIN Trial...
Business Clinical trial results

Profound Medical CAPTAIN Trial Results Presentation

Analysis based on 7 articles · First reported Mar 09, 2026 · Last updated Mar 10, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The presentation of positive clinical outcomes from Profound Medical's CAPTAIN trial is expected to have a significant positive impact on the company's stock and market valuation. Successful trial results could lead to broader adoption of the TULSA Procedure and inclusion in prostate cancer treatment guidelines, benefiting the medical device industry.

Medical Devices Biotechnology Healthcare
Event Summary

Profound Medical Corp. announced the presentation of the first clinical outcomes from its Level 1 post-market CAPTAIN trial at the 41st Annual European Association of Urology Congress in London on March 13, 2026. The trial compares the TULSA Procedure with robotic radical prostatectomy for localized prostate cancer. Dr. Laurence Klotz, an investigator, will present the data. Following the presentation, Profound Medical will host an investor webinar to discuss the clinical relevance and commercial implications of the data, aiming for potential inclusion of the TULSA Procedure in prostate cancer treatment guidelines. Additionally, Profound Medical management will participate in one-on-one investor meetings at the 38th Annual Roth Conference from March 22-24, 2026, in Dana Point, California.

Key Actions
100 Profound Medical presented clinical outcomes from CAPTAIN trial European Association of Urology
90 Profound Medical hosted investor webinar to discuss CAPTAIN data
80 Laurence Klotz presented CAPTAIN study findings European Association of Urology
70 Profound Medical participated in investor meetings Roth Capital Partners
Entities Involved
stock
Profound Medical
Profound Medical is presenting the first clinical outcomes from its CAPTAIN trial, which could significantly advance its TULSA Procedure toward inclusion in prostate cancer treatment guidelines. This event is crucial for the company's market position and future growth.
Importance 100 Sentiment 70
per
Laurence Klotz
Laurence Klotz, a key investigator for the CAPTAIN trial, will present the study's findings at the EAU 2026 Congress and review the data's clinical relevance during Profound Medical's investor webinar. His involvement lends credibility to the trial results.
Importance 80 Sentiment 50
ngo
European Association of Urology
The European Association of Urology is hosting its 41st Annual Congress (EAU 2026) where the CAPTAIN trial results will be presented. This congress serves as a significant platform for disseminating medical advancements.
Importance 60 Sentiment 0
priv
Roth Capital Partners
Roth Capital Partners is hosting its 38th Annual Roth Conference where Profound Medical management will participate in investor meetings. This provides an opportunity for Profound Medical to engage with investors.
Importance 10 Sentiment 0
Relationships
Laurence Klotz related ↔ Profound Medical
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.